Novel trends in systemic therapy of psoriasis

Kurdina M.I.

doi:https://doi.org/

Kurdina M.I.

Fakul'tet fundamental'noĭ meditsiny Moskovskogo gosudarstvennogo universiteta im. M.V. Lomonosova;
FGU TsKBp UD Prezidenta RF, Moskva

Novel trends in systemic therapy of psoriasis

Authors:

Kurdina M.I.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2011;9(5): 54‑59

Read: 1024 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kurdina MI. Novel trends in systemic therapy of psoriasis. Russian Journal of Clinical Dermatology and Venereology. 2011;9(5):54‑59. (In Russ.)

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)

Использование инфографики авторами научных работ

References:

Tzu J., Krulig E., Cardenas V., Kerdel F.A. Biological agents in the treatment of psoriasis. G Ital Dermatol Venereol 2008; 143: 5: 315-327.
Rozenblit M., Lebwohl M. New biologics for psoriasis and psoriatic arthritis. Dermatol Ther 2009; 22: 1: 56-60.
National Institute for Health and Clinical Excellence (NICE). Ustekinumab for the treatment of adults with moderate to severe psoriasis. NICE Technology Appraisal Guidance 180. London UK: NICE 2009.
Buttmann M. Treating multiple sclerosis with monoclonal antibodies: a 2010 update. Expert Rev Neurother 2010; 10: 5: 791-809.
Ryan C., Thrash B., Warren R.B., Menter A. The use of ustekinumab in autoimmune disease. Expert Opin Biol Ther 2010; 10: 4: 587-604.
Santos-Juanes J., Coto-Segura P., Mas-Vidal A., Galache Osuna C. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies. Br J Dermatol 2010; 162: 5: 1144-1146.
Weber J., Keam S.J. Ustekinumab. BioDrugs 2009; 23: 1: 53-61.
Leonardi C.L., Kimball A.B., Papp K.A. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 9625: 1665-1674.
Papp K.A., Langley R.G., Lebwohl M. et al. PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 9625: 1675-1684.
Griffiths C.E., Strober B.E., van de Kerkhof P. et al. ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 2: 118-128.
Centocor, Inc. Findings from landmark study show ustekinumab demonstrated superior efficacy to Enbrel (etanercept) in treatment of moderate to severe plaque psoriasis. News. Horsham PA: Centocor September 18, 2008. Available at: http://www.jnj.com/connect/news/all/20080918_080000. Accessed October 2, 2009.
Gottlieb A., Menter A., Mendelsohn A. et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373: 9664: 633-640.
U.S. Food and Drug Administration (FDA). FDA approves new drug to treat psoriasis. FDA News. Rockville MD: FDA. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm183851.htm. Accessed October 2, 2009.